Clinical Trials Logo

Clinical Trial Summary

This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T lymphocytes (donor adenovirus-specific [AdV] specific CTLs) work in treating CMV or AdV reactivation or infection in participants who have undergone stem cell transplant or solid organ transplant. White blood cells from donors may be able to kill cancer cells in patients with cytomegalovirus or adenovirus that has come back after a stem cell or solid organ transplant.


Clinical Trial Description

PRIMARY OBJECTIVE I. Assess the safety and feasibility of administering virus specific-CTLs from haploidentical donors in transplant patients both solid organ transplantation (SOT) and hematopoietic cell transplantation (HCT) with CMV/AdV infection despite standard therapy. OUTLINE:Patients are assigned to 1 of 2 Cohorts. COHORT A: Patients receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes intravenously (IV). Patients undergo blood, urine, saliva, cerebrospinal fluid (CSF), and bronchoalveolar fluid sample collection on the trial. COHORT B: Patients receive allogeneic adenovirus-specific cytotoxic T Lymphocytes IV. Patients undergo blood, urine, saliva, CSF, and bronchoalveolar fluid sample collection on the trial. After completion of study treatment, participants are followed up at 1 year. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03665675
Study type Interventional
Source Ohio State University Comprehensive Cancer Center
Contact The Ohio State University Comprehensive Cancer Center
Phone 800-293-5066
Email OSUCCCClinicaltrials@osumc.edu
Status Recruiting
Phase Early Phase 1
Start date November 7, 2020
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT02984280 - Specific Respiratory Infections as Triggers of Acute Medical Events N/A
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Recruiting NCT03266627 - Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection Phase 2
Not yet recruiting NCT03325517 - Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics N/A
Not yet recruiting NCT06392451 - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia N/A
Recruiting NCT05183490 - R-MVST Cells for Treatment of Viral Infections Phase 1
Completed NCT04056546 - Interest of Rapid Typing in Adenovirus Infections.
Withdrawn NCT00448994 - Adenovirus and Fungal Load in Pediatric Stem Cell Transplant Patients N/A
Recruiting NCT06299813 - Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus Infection Phase 3
Enrolling by invitation NCT06027879 - Anti-viral T-cell Therapy by Gamma Capture Phase 1/Phase 2
Recruiting NCT02779439 - Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation Phase 1
Terminated NCT02420080 - A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304 N/A
Active, not recruiting NCT01945814 - Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Phase 1
Completed NCT01535885 - Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV Phase 1
Terminated NCT03339401 - The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation Phase 2
Withdrawn NCT01584037 - Adenovirus Vaccine Pregnancy Registry N/A
Withdrawn NCT03532035 - Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia Phase 2
Recruiting NCT02008812 - Ad Sensor-based Real-time Diagnosis of Adenovirus N/A
Active, not recruiting NCT04364178 - Viral Specific T-Lymphocytes to Treat Adenovirus or CMV Phase 1/Phase 2
Recruiting NCT05664126 - Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation Phase 2